Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Clinical Trial Description

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00418743
Study type	Observational
Source	Groupe Francais De Pneumo-Cancerologie
Contact	Christos CHOUAID, Professor
Phone	+33 1 49 28 25 16
Email	christos.chouid@sat.ap-hop-paris.fr
Status	Recruiting
Phase	Phase 2
Start date	December 2005
Completion date	May 2010

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03651219` - Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03958045` - Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma	Phase 2
Completed	`NCT04381910` - Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04885998` - AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)	Phase 1
Active, not recruiting	`NCT03703297` - Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Phase 3
Recruiting	`NCT05903092` - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Terminated	`NCT04422210` - A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Phase 1
Not yet recruiting	`NCT02875457` - Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin	Phase 3
Recruiting	`NCT02577627` - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC	N/A
Recruiting	`NCT02605811` - Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT02542137` - Abscopal Effect for Metastatic Small Cell Lung Cancer	Phase 2
Completed	`NCT02551432` - Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02262897` - The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer	Phase 2
Terminated	`NCT00969306` - Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients	Phase 1
Completed	`NCT01831089` - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors	Phase 1
Completed	`NCT01943578` - Value of Physical Capacity Tests in Lung Cancer	N/A
Completed	`NCT01497873` - A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer	Phase 2
Completed	`NCT00930891` - Bevacizumab in Extensive Small Cell Lung Cancer	Phase 2/Phase 3
Terminated	`NCT00958022` - Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer	Phase 1